Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.
A Phase II Trial Investigating Vemurafenib for the Treatment of Hairy Cell Leukemia
January 24th 2014Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.
Watch
The Black Swan Research Initiative® and a Paradigm Shift in the Treatment of Multiple Myeloma
January 21st 2014Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses the Black Swan Research Initiative® of the IMF and a paradigm shift in the treatment of multiple myeloma.
Watch
The Changing Landscape of Immunotherapies for the Treatment of Melanoma
January 18th 2014Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, comments on the changing landscape of immunotherapies for the treatment of melanoma.
Watch
Phase II Trial of Elderly Patients With Newly Diagnosed Multiple Myeloma
January 10th 2014MarÃa-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology Meeting.
Watch
Tivantinib and Regorafenib for the Treatment of Liver Cancer
January 9th 2014Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the use of tivantinib and regorafenib for the treatment of patients with liver cancer.
Watch
Efficacy and Safety of Idelalisib and Rituximab for Previously Treated CLL
January 8th 2014Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated CLL.
Watch